Literature DB >> 12353123

Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients.

Kristine Nelson1, Declan Walsh, Finbar Sheehan.   

Abstract

Disorders of gastric emptying are being increasingly recognized as the basis for "functional" symptoms in the general population. Recent research suggests that abnormal gastric emptying may also be the cause of common gastrointestinal problems in those with cancer, and can be a complication both of the disease and of its treatment. These disorders are diagnosed by measuring the rate of gastric emptying and comparing it with the normal rate. There are numerous methods of measurement available, each with inherent advantages and disadvantages. Differences in method application and a lack of standardization limit the extent to which results from different institutions can be compared. Because of the limitations of existing methods, new technology is frequently being evaluated. Radionuclide measurement is the current method of choice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12353123     DOI: 10.1007/s00520-002-0340-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  16 in total

1.  Prognostic Value of Heart Rate Variability in Patients With Cancer.

Authors:  Ying Guo; Shalini Koshy; David Hui; J Lynn Palmer; Ki Shin; Mehtap Bozkurt; Syed Wamique Yusuf
Journal:  J Clin Neurophysiol       Date:  2015-12       Impact factor: 2.177

2.  The role of electrogastrography and gastrointestinal hormones in chemotherapy-related dyspeptic symptoms.

Authors:  Giuseppe Riezzo; Caterina Clemente; Silvana Leo; Francesco Russo
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

3.  Gastrointestinal symptoms are associated with trajectories of chemotherapy-induced nausea.

Authors:  Komal Singh; Kord M Kober; Steven M Paul; Marilyn Hammer; Fay Wright; Yvette P Conley; Jon D Levine; Christine Miaskowski
Journal:  Support Care Cancer       Date:  2019-08-19       Impact factor: 3.603

4.  Ghrelin partially protects against cisplatin-induced male murine gonadal toxicity in a GHSR-1a-dependent manner.

Authors:  Shannon D Whirledge; Jose M Garcia; Roy G Smith; Dolores J Lamb
Journal:  Biol Reprod       Date:  2015-01-28       Impact factor: 4.285

5.  Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function.

Authors:  E Z H Sung; R P Arasaradnam; E M Jarvie; S James; S J Goodyear; R A Borman; D Snead; G J Sanger; C U Nwokolo
Journal:  Mol Biol Rep       Date:  2012-06-29       Impact factor: 2.316

6.  Heart rate variability as a measure of autonomic dysfunction in men with advanced cancer.

Authors:  Y Guo; J L Palmer; F Strasser; S W Yusuf; E Bruera
Journal:  Eur J Cancer Care (Engl)       Date:  2013-04-30       Impact factor: 2.520

7.  Animal models of anorexia and cachexia.

Authors:  Mark Daniel Deboer
Journal:  Expert Opin Drug Discov       Date:  2009-11-01       Impact factor: 6.098

8.  Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus).

Authors:  Bart C De Jonghe; Charles C Horn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-18       Impact factor: 3.619

9.  Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer.

Authors:  Tomofumi Miura; Shuichi Mitsunaga; Masafumi Ikeda; Izumi Ohno; Hideaki Takahashi; Hidetaka Suzuki; Ai Irisawa; Takeshi Kuwata; Atsushi Ochiai
Journal:  Support Care Cancer       Date:  2018-05-18       Impact factor: 3.603

10.  Brain Fos expression induced by the chemotherapy agent cisplatin in the rat is partially dependent on an intact abdominal vagus.

Authors:  Charles C Horn
Journal:  Auton Neurosci       Date:  2009-04-10       Impact factor: 3.145

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.